Venquis Therapeutics
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Venquis Therapeutics
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Harnessing the power of protein degradation to deliver precision medicines for oncology and beyond
Venquis Therapeutics has developed a small molecule monovalent degrader discovery platform named CIPD: Chemically Induced Protein Degrader
Our initial compounds target clinically relevant proteins in a mutant-selective fashion: degrading the driver-mutant proteins while sparing their corresponding endogenous wild-type proteins
This is a powerful approach for addressing oncology and other classes of target proteins
We discover and develop mechanistically differentiated targeted small molecule direct protein degraders. These are not molecular glues or PROTACs. These directly bind the Protein Of Interest, which is then targeted for cellular degradation
We developed a focused chemical library screening platform to identify novel direct protein degraders
We simultaneously use structure-based analog design from known chemical binders to create new direct degraders
17150 Via Del Campo STE 105, San Diego, California 92127, United States
Copyright © 2024 Venquis Therapeutics - All Rights Reserved.